Precision nanomedicine-based diagnostics and therapeutics for refractory malignancies

基于纳米医学的精准诊断和治疗难治性恶性肿瘤

• 批准号: nhmrc : 1091261
• 负责人: Prof John Gooding
• 金额: $ 488.73万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Program Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/precision-nanomedicine-based-refractory-malignancies/519321
• 关键词: Precision; nanomedicine; based; diagnostics; therapeutics

The vast majority of cancer patients die of their disease due to the emergence of drug resistant cancer cells or metastatic disease that is diagnosed at late stages. Our program aims to develop new types of therapy to specifically target aggressive cancers. To detect cancer early and evaluate the effectiveness of cancer therapy, we will develop sensitive diagnostic tools and devices. This research has application to both childhood and adult cancers.

绝大多数癌症患者死于他们的疾病，原因是出现了耐药癌细胞或在晚期被诊断为转移的疾病。我们的计划旨在开发专门针对侵袭性癌症的新型治疗方法。为了及早发现癌症并评估癌症治疗的效果，我们将开发敏感的诊断工具和设备。这项研究适用于儿童和成人癌症。